TAS-2940
- Generic Name
- TAS-2940
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
Phase 1
Active, not recruiting
- Conditions
- Breast CancerSolid TumorGlioblastomaNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT04982926
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇫🇷CLCC Gustave Roussy, Villejuif, Cedex, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath